Managing a patient with presumed testosterone-secreting ovarian tumor.
We report the case of a 70-year-old woman who was presumed to have right ovarian testosterone-secreting tumor and was treated with long-acting gonadotropin-releasing hormone agonist therapy plus add-back hormone replacement therapy. The patient presented with various medical problems including hypertension, intracranial hemorrhage, myocardial infarction, unstable angina pectoris, and poor control of diabetic mellitus and had exhibited rapid symptoms of androgen excess such as progressive hirsutism and bilateral temporal balding for half a year. Tumor survey was negative except for an elevated testosterone level. Renal vein catheterization successfully detected a right ovarian androgen-secreting tumor. Because the patient was deemed medically unable to tolerate surgery, she received an alternative treatment consisting of 6 months of gonadotropin-releasing hormone-agonist (GnRH-a) and add-back hormone replacement therapy (HRT). Serum testosterone levels returned to normal limits after administration of the first dose of GnRH-a. A follow-up tumor survey was negative. The patient has been alive and free of disease for 8 months after six doses of GnRH-a. We conclude that this strategy might be used as urgent therapy in a medically compromised patient with presumed ovarian androgen-secreting tumor.
Lee
W L
WL
Department of Medicine, Veterans General Hospital-Taipei, Taipei, Taiwan.
Wang
P H
PH
Tseng
H S
HS
Lin
H D
HD
Yuan
C C
CC
Chao
H T
HT
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D017273:Goserelin / Q000627:therapeutic use*; D020249:Hormone Replacement Therapy; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D013739:Testosterone / Q000378:metabolism*
D018931:Antineoplastic Agents, Hormonal; D004966:Estrogens, Conjugated (USP); D017273:Goserelin; D013739:Testosterone